Your source for the latest medtech news from AdvaMed® and our members.
Inflammatix, a pioneering host response diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the TriVerity™ Test System (TriVerity), a first-in-class molecular test for…
On the Medtech POV podcast , AdvaMed® President and CEO Scott Whitaker sat down with Jacob “Jake” Leach, Executive Vice President and Chief Operating Officer at Dexcom, to discuss the…
MedTechVets, a leading nonprofit organization dedicated to helping military veterans transition and find a career with purpose in the Medical Technology Industry through education, mentoring, and networking, is pleased to…
Francis Medical, Inc., a privately-held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney and bladder cancer, today announced the completion…
If you have media inquiries, please contact:
Jim Jeffries, Senior Vice President, Public Affairs, 206-225-5226
On the Medtech POV podcast, AdvaMed® President and CEO Scott Whitaker sat down with Martina Navratilova and Chris Evert, professional tennis legends who met as teen-age competitors and whose friendship…
AdvaMed®, the Medtech Association, commended the House of Representatives’ bipartisan Task Force on Artificial Intelligence for urging the Centers for Medicare & Medicaid Services (CMS) to develop a formalized payment…
AdvaMed®, the Medtech Association, asked the United States Court of Appeals to support a fair and balanced approach to patent damages.
AdvaMed®, the Medtech Association, released the following statement from President and CEO Scott Whitaker on President-elect Trump’s announcement that he intends to nominate Dr. Martin Makary to Lead FDA:
Brought to you by AdvaMed®, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.
AdvaMed®, the Medtech Association, recently published a technical white paper outlining concerns with third-party modification of interventional X-ray equipment, which can pose unforeseen risks for patients and providers.